Literature DB >> 1834643

Disulfide cross-linking of caldesmon to actin.

P Graceffa1, A Jancsó.   

Abstract

Treatment of a solution of actin and smooth muscle caldesmon with 5,5'-dithiobis(2-nitrobenzoic acid) results in the formation of a disulfide cross-link between the C-terminal penultimate residue Cys-374 of actin and Cys-580 in caldesmon's C-terminal actin-binding region. Therefore, these 2 residues are close in the actin-caldesmon complex. Since myosin also binds to actin in the vicinity of Cys-374 and since caldesmon inhibits actomyosin ATPase activity by the reduction of myosin binding to actin, then the inhibition might be by caldesmon sterically hindering or blocking myosin's interaction with actin. [Ca2+]Calmodulin, which reverses the inhibition of the ATPase activity, decreases the yield of the cross-linked species, suggesting a weakening of the caldesmon-actin interaction in the cross-linked region. It is possible to maximally cross-link one caldesmon molecule/every three actin monomers, in the absence or presence of tropomyosin, clearly ruling out an elongated, end-to-end alignment of caldesmon on the actin filament in vitro, and raising the possibility that the N-terminal part of caldesmon projects out from the filament. Reaction of 5,5'-dithiobis(2-nitrobenzoic acid)-modified actin with caldesmon leads to the same disulfide cross-linked product between actin and caldesmon Cys-580, enabling the specific labeling of the other caldesmon cysteine, residue 153, in the N-terminal part of caldesmon with a spectroscopic probe.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1834643

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  X-ray scattering study of activated Arp2/3 complex with bound actin-WCA.

Authors:  Malgorzata Boczkowska; Grzegorz Rebowski; Maxim V Petoukhov; David B Hayes; Dmitri I Svergun; Roberto Dominguez
Journal:  Structure       Date:  2008-05       Impact factor: 5.006

2.  Utilization of troponin C as a model calcium-binding protein for mapping of the calmodulin-binding sites of caldesmon.

Authors:  A A Polyakov; N B Gusev
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

3.  Disulfide cross-linked antiparallel actin dimer.

Authors:  Philip Graceffa; Eunhee Lee; Walter F Stafford
Journal:  Biochemistry       Date:  2013-01-30       Impact factor: 3.162

4.  Structural connectivity in actin: effect of C-terminal modifications on the properties of actin.

Authors:  R H Crosbie; C Miller; P Cheung; T Goodnight; A Muhlrad; E Reisler
Journal:  Biophys J       Date:  1994-11       Impact factor: 4.033

5.  Caldesmon exhibits a clustered distribution along individual chicken gizzard native thin filaments.

Authors:  K Mabuchi; Y Li; A Carlos; C L Wang; P Graceffa
Journal:  J Muscle Res Cell Motil       Date:  2001       Impact factor: 2.698

6.  Location and functional characterization of myosin contact sites in smooth muscle caldesmon.

Authors:  A V Vorotnikov; S B Marston; P A Huber
Journal:  Biochem J       Date:  1997-11-15       Impact factor: 3.857

7.  Localization and characterization of a 7.3-kDa region of caldesmon which reversibly inhibits actomyosin ATPase activity.

Authors:  J M Chalovich; J Bryan; C E Benson; L Velaz
Journal:  J Biol Chem       Date:  1992-08-15       Impact factor: 5.157

8.  Disulphide cross-linking of smooth-muscle and non-muscle caldesmon to the C-terminus of actin in reconstituted and native thin filaments.

Authors:  P Graceffa; L P Adam; W Lehman
Journal:  Biochem J       Date:  1993-08-15       Impact factor: 3.857

9.  Flexation of caldesmon: effect of conformation on the properties of caldesmon.

Authors:  R H Crosbie; J M Chalovich; E Reisler
Journal:  J Muscle Res Cell Motil       Date:  1995-10       Impact factor: 2.698

10.  Electron microscopic images suggest both ends of caldesmon interact with actin filaments.

Authors:  K Mabuchi; J J Lin; C L Wang
Journal:  J Muscle Res Cell Motil       Date:  1993-02       Impact factor: 2.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.